This is the authors' abstract. We don't add key points for this paper.
INTRODUCTION: gene, which could mitigate the pathophysiological and clinical symptoms of CF. AREAS COVERED: We provide an overview of non-viral mRNA therapies for CF and their ongoing clinical trials. We begin with a discussion of the pathophysiological functions of CFTR and clinical symptoms of CF. We provide a summary of conventional treatments, modulator therapies, and potential gene therapies for CF. We discuss the pertinence of mRNA therapies for CF as well as the challenges associated with mRNA delivery. We conclude with an overview of non-viral vectors for mRNA delivery and a summary of clinical trials for CFTR mRNA therapies. Literature searches for this review were performed using databases (Google Scholar and PubMed). EXPERT OPINION: With continued innovation and overcoming of delivery challenges, mRNA therapies hold great potential for the treatment of people with CF, regardless of mutation.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Gill et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: